Thanks, Rob. Good morning, everyone. First, let me say that I share Rob’s sentiment and I hope everyone remains safe and healthy. The first two months of the quarter were very active for Horizon. However, activity slowed in March as many technology and life science companies were distracted by the dislocation and complexity of the impact of COVID-19 on their business. From March through today, we have continued to carefully review new opportunities through the lens of the COVID-19 pandemic and the resulting impact of a rapidly changing economic environment. That said, we continued to observe significant activity and competition in the venture lending market for investments in high-quality companies with strong liquidity, management and investor support, as well as products and services that are relevant and in demand today. There were some segments of our market review with caution such as consumer oriented tech companies. While other segments we view with more optimism such as life science vaccine or drug development companies. These companies appear to be seeing continued demand for new drugs and vaccines and have strong balance sheets to further their development well into 2021. We are seeing some near-term dislocation in the healthcare technology market as hospitals are focused on COVID-19 and private practice physicians are essentially closed for business. But we believe demand for healthcare tech products will bounce back as the economy opens up over the next few months and pent-up demand for healthcare services re-emerges. In the quarter, we made a total of $51 million in investments to three new portfolio companies and three existing portfolio companies. This resulted in growth in our portfolio for the eighth consecutive quarter or $25 million on a net cost basis. The onboarding yields to the investments we made in the first quarter were 11.2%. We experienced two loan portfolio prepayments during the quarter, totaling $16 million which contributed to our NII. In addition, the prepayment and accelerated income from these events helped drive a debt portfolio yield for the quarter of 13.2%. Our debt portfolio yields continues to lead the BDC industry. Additionally, as Rob noted on our last call, structuring investments with warrants and equity rights is a key aspect of our predictive pricing strategy. Warrants are a cashless investment for Horizon, which served as an additional value generator. During the quarter, we received proceeds of over $5.5 million from warrants and portfolio companies that experienced M&A transactions and from the equity and public company. In Q1, we closed $55 million in new loan commitments and approvals and ended the quarter with a committed backlog of $44 million compared to $50 million at the end of 2019. Our pipeline of new opportunities as of today is $440 million. In addition, post quarter end, we increased our loan approvals and commitments from approximately $44 million to approximately $104 million today. All of the increase in our committed backlog is from life science or healthcare-related transactions with typical milestone-driven or tranched funding patents. From a portfolio perspective, despite the economic environment, we believe we remain well positioned with our committed backlog and pipeline to selectively grow our portfolio in the first half of the year. As of March 31, we held warrant and equity positions in 70 portfolio companies with a fair value of 10 million. During the quarter, one of our warrant portfolio companies, Sys-Tech whose loan had been repaid in 2017 completed an M&A transaction and Horizon received approximately $2.3 million in warrant proceeds. Bridge2 Solutions was also acquired in the quarter and along with the repayment of our principal balance and accelerated income and fees. Horizon received warrant proceeds of approximately $2.8 million. Post quarter end, our portfolio company HealthEdge was sold to Blackstone and along with repayment of our principal balance and accelerated income and fees, Horizon received warrant proceeds of approximately $500,000. For the first two months of the first quarter seemed like business as usual, it was very much business as unusual in March. As we’ve communicated previously, we always engage with all of our venture debt portfolio companies on a regular and as needed basis. As the economy essentially shut down, the ability of companies to raise additional capital became less certain. Accordingly, we ramped up contact with our portfolio companies and their investors to get a keen sense of their near-term needs, expectations and financing plans. A few of our portfolio companies have clearly been impacted by the national shutdown. As of March 31, we have six two-rated credits in our portfolio. We are consistently in touch with those portfolio companies and we’ll work with them as much as necessary to help them manage through the short and medium term dislocation on their business. One of the ways we have done so is to quickly respond to requests, but necessary consents and waivers for our borrowers to access the SBAs paycheck protection program. The COVID-19 situation remains very fluid. Thus, we will continue to closely manage our portfolio. I would now like to provide a brief update on some credits we have discussed last quarter. We collected a $5 million pay down on our IgnitionOne loan in February and placed it on nonaccrual. The balance of our loan remained secured by private stock value well in excess of our balance. Horizon kept its Audacy loan on nonaccrual as of March 31 and carries the loan at fair value of $1.8 million, an increase from December 31 due to some favorable regulatory approvals. The transaction to acquire Audacy continues and is expected to close later this year. Subsequent to quarter end, we received proceeds of $600,000 in settlement of our loan to [indiscernible] which loan was fair valued at $500,000 at March 31. Turning now to the venture capital environment. According to PitchBook, approximately $34 billion was invested in VC-backed companies in the first quarter of 2020. But as one would expect the last few weeks are a significant reduction in activity. To be clear, though, investment activity has not stopped and we believe they remains opportunities for selective investment despite the market dislocation. In terms of VC fundraising, $21 billion was raised in the first quarter, a strong start to the year. However, we would obviously not expect similar numbers in the near term. A positive note is that VC funds have $120 billion of dry powder available for investing. In terms of VC backed exit activity, there were 10-venture backed IPOs in the first quarter contributing to a total exit value of $19 billion. With COVID-19, we expect 2020 IPO activity will decrease considerably from 2019, although we could still anticipate some healthcare life science sector IPOs later in the year. Turning now to our core markets. In the first quarter, we saw greater activity in our life science and healthcare technology markets providing funding to two new portfolio companies, a $20 million venture loan to Castle Creek Biosciences a developer of gene therapies and a $15 million venture loan to a digital health company providing remote cardiac patient monitoring. We also funded an additional $4 million to CSA Medical, one of our existing life science portfolio companies. Finally, we made one select investment in the technology sector during the quarter, funding a $10 million venture loan to a new portfolio company that is creating access for high quality online education. As we look ahead, we will continue to closely monitor the economic landscape and prudently originate new loans that meet our current underwriting criteria, while we keep a sharp focus on our current and diverse portfolio of senior secured loans. Our actions to strengthen our balance sheet over the past couple of years, including raising $16 million of equity early in the first quarter under our ATM facility, put Horizon in a solid liquidity position with a leverage below our target. We believe our liquidity position will allow us to navigate through the current environment and ultimately deliver additional long-term shareholder value. With that, I will now turn the call over to Dan.